Unleashing the Potential of Tau Oligomer Inhibition™
Oligomerix® Vision
To discover novel and differentiated small molecules and biomarkers focused on tau oligomer inhibition for the disease-modifying treatment of Alzheimer’s disease and other related neurodegenerative diseases
News & Upcoming Events
Bio CEO & Investor Conference
Date, & Time: Monday, February 10, 2020; 2:30 PM
Venue: Marriott Marquis New York, New York
TAU2020 Global Conference
Date, & Time: Wednesday February 12, 2020; 7:30 AM-6:40 PM
Poster Session: A small molecule inhibitor of tau self-association is efficacious in both htau and JNPL3 mouse models of tauopathy
Venue: Marriott Marquis Washington, D.C.
Our recent publication of an in vivo proof-of-concept study showed that an oral small molecule drug for Alzheimer’s disease reduced the level of tau aggregates linked to neurotoxicity and disease progression.
Oligomerix and Feinstein Institutes Publish In Vivo Alzheimer’s Disease Treatment Data
Click here to read the full news story